COVID-19 Treatment Recommendations for Outpatients



*Rebound symptoms have occurred with Paxlovid use. Do not repeat Paxlovid or prolong course.
**Molnupiravir has been related to teratogenicity in both females and males of child bearing age, use cautiously

Approved by Antimicrobial P&T Subcommittee: 01/2022, 03/2022, 07/2022, 10/2022, 01/2024
Approved by Pharmacy & Therapeutics Committee: 01/2022, 03/2022 (expedited), 08/2022, 12/2022, 02/2024

COVID-19 Treatment Recommendations for Outpatients

Appendix A: Risk Factors for Progressing to Severe COVID-19 and/or Hospitalization:

*Not listed in order of degree of risk conferred

- Body mass index (BMI) ≥ 25 (age 12-17 yo BMI ≥ 85th percentile)
- Pregnancy
- Chronic kidney disease
- Diabetes
- Immunosuppressive disease
- Currently receiving immunosuppressive treatment
- ≥ 65 years of age
- Cardiovascular disease (including congenital heart disease)
- Hypertension
- Chronic obstructive pulmonary disease/other chronic respiratory disease (including asthma, interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders, for example, cerebral palsy or Down Syndrome, OR
- A medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
- Other risk factors for severe COVID as identified by CDC (https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html)
- Or most recent criteria in FDAs most recent EUA update

Approved by Antimicrobial P&T Subcommittee: 01/2022, 03/2022, 07/2022, 10/2022, 01/2024
Approved by Pharmacy & Therapeutics Committee: 01/2022, 03/2022 (expedited), 08/2022, 12/2022, 02/2024

COVID-19 Treatment Recommendations for Outpatients

Appendix B: Significant Drug Interactions with Paxlovid[a]

Paxlovid Co-administration CONTRAINDICATED:		Use CAUTION when prescribing Paxlovid. Withhold medication or reduce dose if clinically appropriate and monitor closely. If withholding medication is not clinically appropriate, use alternative COVID-19 therapy	
• Alfuzosin • Amiodarone • Apalutamide • Bosentan • Carbamazepine • Cisapride • Clopidogrel • Clozapine • Colchicine in patients with renal and/or hepatic impairment • Disopyramide • Dofetilide • Dronedarone • Eplerenone • Ergot derivatives • Flecainide • Flibanserin • Glecaprevir/pibrentasvir • Ivabradine • Lovastatin	• Lumateperone • Lurasidone • Mexiletine • Phenobarbital • Phenytoin • Pimozide • Piroxicam • Propafenone • Quinidine • Ranolazine • Rifampin • Rifapentine • Rivaroxaban • Sildenafil for pulmonary hypertension • Simvastatin • St. John's Wort • Tadalafil for pulmonary hypertension • Ticagrelor • Vorapaxar	• Alprazolam • Amlodipine • Atorvastatin • Avanafil • Bupropion • Clonazepam • Codeine • Corticosteroids, systemic • Cyclosporine[b] • Diazepam • Digoxin • Diltiazem • Everolimus[b] • Ethinyl estradiol • Fentanyl • Hydrocodone • Lomitapide • Meperidine (pethidine) • Methadone • Midazolam (oral) • Nicardipine	• Nifedipine • Oxycodone • Propoxyphene • Quetiapine • Rosuvastatin • Salmeterol • Sildenafil for erectile dysfunction • Silodosin • Sirolimus[b] • Suvorexant • Tacrolimus[b] • Tadalafil for erectile dysfunction • Tamsulosin • Tramadol • Trazodone • Triazolam • Vardenafil • Warfarin

[a:] Please refer to Paxlovid® Package Insert or University of Liverpool website (https://www.covid-19-druginteractions.org/) for a complete list of drug interactions.

[b:] Requires expert recommendations prior to adjusting medication

Approved by Antimicrobial P&T Subcommittee: 01/2022, 03/2022, 07/2022, 10/2022, 01/2024
Approved by Pharmacy & Therapeutics Committee: 01/2022, 03/2022 (expedited), 08/2022, 12/2022, 02/2024

COVID-19 Treatment Recommendations for Outpatients

References:

1) Paxlovid Package Insert 9/25/2023
2) Remdesivir Package Insert as of 9/25/2023
3) Molnupiravir EUA as of 9/25/2023
4) Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. DOI: 10.1056/NEJMoa2116846.

Approved by Antimicrobial P&T Subcommittee: 01/2022, 03/2022, 07/2022, 10/2022, 01/2024
Approved by Pharmacy & Therapeutics Committee: 01/2022, 03/2022 (expedited), 08/2022, 12/2022, 02/2024